ELSI Implications of Prioritizing Biological Therapies in the Times of COVID-19

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

ELSI Implications of Prioritizing Biological Therapies in the Times of COVID-19. / Druedahl, Louise C.; Lebret, Audrey; Minssen, Timo.

I: Journal of Law, Medicine & Ethics, Bind 48, Nr. 3, 10.2020, s. 579-582.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Druedahl, LC, Lebret, A & Minssen, T 2020, 'ELSI Implications of Prioritizing Biological Therapies in the Times of COVID-19', Journal of Law, Medicine & Ethics, bind 48, nr. 3, s. 579-582. https://doi.org/10.1177/1073110520958884

APA

Druedahl, L. C., Lebret, A., & Minssen, T. (2020). ELSI Implications of Prioritizing Biological Therapies in the Times of COVID-19. Journal of Law, Medicine & Ethics, 48(3), 579-582. https://doi.org/10.1177/1073110520958884

Vancouver

Druedahl LC, Lebret A, Minssen T. ELSI Implications of Prioritizing Biological Therapies in the Times of COVID-19. Journal of Law, Medicine & Ethics. 2020 okt.;48(3):579-582. https://doi.org/10.1177/1073110520958884

Author

Druedahl, Louise C. ; Lebret, Audrey ; Minssen, Timo. / ELSI Implications of Prioritizing Biological Therapies in the Times of COVID-19. I: Journal of Law, Medicine & Ethics. 2020 ; Bind 48, Nr. 3. s. 579-582.

Bibtex

@article{ae8871479f3a436ca406da103d3fb9c0,
title = "ELSI Implications of Prioritizing Biological Therapies in the Times of COVID-19",
abstract = "There is no doubt that COVID-19 will have a substantial impact on access to biologics and biosimilar uptake, as well as on the related ethical, legal, and social dimensions of prioritization decisions. This holds especially true for Denmark and European markets, where governments are expected to cover most of the pharmaceutical needs of their citizens and where the crisis has been leading to an important reduction of available resources. In this paper we make four key comments relating to (1) broader ethico-legal dimensions of prioritizations in Europe, (2) human rights law and (3) regulatory aspects of access, diversification, vulnerability and systemic trust, and (4) additional challenges posed by COVID-19.",
author = "Druedahl, {Louise C.} and Audrey Lebret and Timo Minssen",
year = "2020",
month = oct,
doi = "10.1177/1073110520958884",
language = "English",
volume = "48",
pages = "579--582",
journal = "Law, medicine & health care : a publication of the American Society of Law & Medicine",
issn = "1073-1105",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - ELSI Implications of Prioritizing Biological Therapies in the Times of COVID-19

AU - Druedahl, Louise C.

AU - Lebret, Audrey

AU - Minssen, Timo

PY - 2020/10

Y1 - 2020/10

N2 - There is no doubt that COVID-19 will have a substantial impact on access to biologics and biosimilar uptake, as well as on the related ethical, legal, and social dimensions of prioritization decisions. This holds especially true for Denmark and European markets, where governments are expected to cover most of the pharmaceutical needs of their citizens and where the crisis has been leading to an important reduction of available resources. In this paper we make four key comments relating to (1) broader ethico-legal dimensions of prioritizations in Europe, (2) human rights law and (3) regulatory aspects of access, diversification, vulnerability and systemic trust, and (4) additional challenges posed by COVID-19.

AB - There is no doubt that COVID-19 will have a substantial impact on access to biologics and biosimilar uptake, as well as on the related ethical, legal, and social dimensions of prioritization decisions. This holds especially true for Denmark and European markets, where governments are expected to cover most of the pharmaceutical needs of their citizens and where the crisis has been leading to an important reduction of available resources. In this paper we make four key comments relating to (1) broader ethico-legal dimensions of prioritizations in Europe, (2) human rights law and (3) regulatory aspects of access, diversification, vulnerability and systemic trust, and (4) additional challenges posed by COVID-19.

U2 - 10.1177/1073110520958884

DO - 10.1177/1073110520958884

M3 - Journal article

C2 - 33021187

VL - 48

SP - 579

EP - 582

JO - Law, medicine & health care : a publication of the American Society of Law & Medicine

JF - Law, medicine & health care : a publication of the American Society of Law & Medicine

SN - 1073-1105

IS - 3

ER -

ID: 242517952